(Reuters) -German vaccine maker BioNTech said on Tuesday that it plans to expand its investment in the United Kingdom by up ...

The FDA had given Pfizer and Moderna until May 17 to propose changes to the labels of their COVID-19 vaccines or challenge ...

COVID vaccine maker BioNTech (NASDAQ:BNTX) has reached an agreement with the U.K. to invest £1B ($1.3B) in the country over ...

Advisers to the Food and Drug Administration met Thursday to help decide which variant of the virus that causes COVID should ...

The FDA has told vaccine manufacturers to expand the warning labels on their COVID-19 shots with more information about the ...

Roughly five months after AstraZeneca scrapped a major investment plan in its home country, the United Kingdom has found a ...

Government signs deal to see huge investment in mRNA vaccine manufacturing which could help tackle the next pandemic and ...

The US Food and Drug Administration will now require Covid-19 vaccines from Pfizer/BioNTech and Moderna to use expanded ...

BioNTech will invest up to £1bn in UK life sciences over 10 years, launching new AI and R&D centres in London and Cambridge.

Hundreds of highly skilled jobs will be created, and new research centres will be set up aimed at making new advances in ...

An eight-member panel voted unanimously against wider use of Pfizer’s Talzenna in advanced prostate cancer. Elsewhere, U.K.

BioNTech said it plans to invest up to 1 billion pounds ($1.34 billion) over the next 10 years to expand its research and development activities for innovative medicines in the U.K.